Serum Troponin-I as a prognostic marker in acute exacerbated chronic obstructive pulmonary disease patients

Youssef, Abdel Rahim I.; Hassan, Adel Salah A.; El-Ghamry, Reda; Ahmed, Ayman

doi:10.1016/j.ejcdt.2013.07.002

Cited by 8 publications

(18 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study also reported association of elevated troponin with lower pulse oximetry and hypercapnoea. 9 In the present study, need for invasive or noninvasive ventilation was found to be significantly high (p=0.016) in patients with positive cTnI as compared to patients having levels of cTnI<0.01ng/ml. This finding is in agreement with results put forward in other studies where the authors have reported a statistically significant difference in cTnI positivity between patients who needed ventilation and those who did not.…”

Section: Discussionsupporting

confidence: 39%

“…13 It has been observed that with a cut off value of ≤0.055ng/ml, cTnI has sensitivity and specificity of 75% and 68% respectively as regards survival with a negative predictive value of 91.7%. 9 Martin et al have also found that elevated cTnI levels were predictors of 18 month overall survival in patients hospitalized for AECOPD.…”

Section: Discussionmentioning

confidence: 92%

“…Similar findings have also been reported in some other studies. 9,15 Amongst 50 patients included in the study, cTnI was found to be positive in 34% of the patients. There is another study which reported positive cTnI in 32% of patients of AECOPD.…”

Section: Discussionmentioning

confidence: 95%

“…The serum concentration of cTnI≥0.01ng/ml was considered to be positive. 9 Patients were followed up for 30 days for mortality and morbidity in terms of length of hospital stay. Data was entered and analyzed by SPSS package and two sided pvalues<0.05 were considered statistically significant.…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Cardiac troponin I as mortality predictor in acute exacerbation of chronic obstructive pulmonary disease

et al. 2017

View full text Add to dashboard Cite

Background: Comorbidities are important determinants of outcome and quality of life of patients with chronic obstructive pulmonary disease (COPD). The risk of cardiovascular events in COPD patients is three to five-fold high. COPD is often associated with right ventricular hypertrophy and pulmonary hypertension. Various studies have associated levels of cardiac troponin I (cTnI) with severity and duration of acute exacerbation of COPD (AECOPD). The objective of the present study was to assess the usefulness of serum cTnI as mortality predictor in AECOPD patients.Methods: An observational, prospective and non interventional study was conducted in 50 patients with AECOPD admitted in the pulmonary medicine emergency or ward of a tertiary care hospital of Northern India. AECOPD was diagnosed according to Global Initiative for chronic obstructive lung disease guidelines. cTnI levels were estimated within 24 hours of admission by method based on chemiluminiscence along with routine investigations. Levels ≥ 0.01ng/ml were taken as positive. The patients were followed up for 30days for outcome in terms of mortality and morbidity. Data was entered and analyzed by SPSS package and two sided p values<0.05 were considered statistically significant.Results: The serum cTnI was found to be positive in 34% of patients with AECOPD. The in- hospital mortality was significantly low in patients having cTnI <0.01ng/ml as compared to patients with cTnI ≥0.01ng/ml. The patients with cTnI levels ≥0.01ng/ml had significantly higher mean PaCO2 levels and higher requirement for invasive or noninvasive ventilation during hospital stay as compared to patients having cTnI <0.01ng/ml (p=0.04 and 0.016 respectively).Conclusions: Levels of cTnI≥0.01ng/ml may be considered as a biomarker to predict mortality in AECOPD patients.

show abstract

Section: Discussionsupporting

confidence: 39%

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 95%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Cardiac troponin I as mortality predictor in acute exacerbation of chronic obstructive pulmonary disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The elevated serum activities of these heart damage‐associated enzymes could be attributed to the massive increment in free radical amounts and their effects on the cellular membrane of cardiomyocytes leading to leakage of these enzymes from the damaged membranes of cells into the circulation 69–71,78 . Furthermore, cardiac troponin I is an early emerging, highly sensitive and long‐lasting marker with heart specificity; as it is considered as an appropriate marker for evaluation of myocardial damage 71,79 . For instance, the increment in serum troponin I level of patients shortly following chemotherapy is considered as a strong predictor of ventricular dysfunction as well as poor cardiac outcome 80,81 .…”

Section: Discussionmentioning

confidence: 99%

The cardioprotective effects of nano‐curcumin against doxorubicin‐induced cardiotoxicity: A systematic review

et al. 2022

View full text Add to dashboard Cite

Although the chemotherapeutic drug, doxorubicin, is commonly used to treat various malignant tumors, its clinical use is restricted because of its toxicity especially cardiotoxicity. The use of curcumin may alleviate some of the doxorubicin‐induced cardiotoxic effects. Especially, using the nano‐formulation of curcumin can overcome the poor bioavailability of curcumin and enhance its physicochemical properties regarding its efficacy. In this study, we systematically reviewed the potential cardioprotective effects of nano‐curcumin against the doxorubicin‐induced cardiotoxicity. A systematic search was accomplished based on Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines for the identification of all relevant articles on “the role of nano‐curcumin on doxorubicin‐induced cardiotoxicity” in the electronic databases of Scopus, PubMed, and Web of Science up to July 2021. One hundred and sixty‐nine articles were screened following a predefined set of inclusion and exclusion criteria. Ten eligible scientific papers were finally included in the present systematic review. The administration of doxorubicin reduced the body and heart weights of mice/rats compared to the control groups. In contrast, the combined treatment of doxorubicin and nano‐curcumin increased the body and heart weights of animals compared with the doxorubicin‐treated groups alone. Furthermore, doxorubicin could significantly induce the biochemical and histological changes in the cardiac tissue; however, coadministration of nano‐curcumin formulation demonstrated a pattern opposite to the doxorubicin‐induced changes. The coadministration of nano‐curcumin alleviates the doxorubicin‐induced cardiotoxicity through various mechanisms including antioxidant, anti‐inflammatory, and antiapoptotic effects. Also, the cardioprotective effect of nano‐curcumin formulation against doxorubicin‐induced cardiotoxicity was higher than free curcumin.

show abstract

Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis

Pavasini¹,

D’Ascenzo

Campo

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

Serum Troponin-I as a prognostic marker in acute exacerbated chronic obstructive pulmonary disease patients

Cited by 8 publications

References 23 publications

Cardiac troponin I as mortality predictor in acute exacerbation of chronic obstructive pulmonary disease

Cardiac troponin I as mortality predictor in acute exacerbation of chronic obstructive pulmonary disease

The cardioprotective effects of nano‐curcumin against doxorubicin‐induced cardiotoxicity: A systematic review

Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis

Contact Info

Product

Resources

About